Haploinsufficient Transcription Factors in Myeloid Neoplasms

被引:0
作者
Martinez, Tanner C. [1 ,2 ]
McNerney, Megan E. [1 ]
机构
[1] Univ Chicago, Dept Pathol, Med Comprehens Canc Ctr, Sect Hematol Oncol,Dept Pediat, 5841 S Maryland Ave, Chicago, IL 60637 USA
[2] Univ Chicago, Med Scientist Training Program, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
hematopoietic stem cell; acute myeloid leukemia; myelodysplastic syndrome; transcription factor; haploinsufficiency; aneuploidy; HEMATOPOIETIC STEM-CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; TUMOR-SUPPRESSOR GENE; C/EBP-ALPHA; MYELODYSPLASTIC-SYNDROME; BIOLOGICAL IMPLICATIONS; DIFFERENTIATION BLOCK; TARGET GENES; DNA-BINDING; FACTOR PU.1;
D O I
10.1146/annurev-pathmechdis-051222-013421
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Many transcription factors (TFs) function as tumor suppressor genes with heterozygous phenotypes, yet haploinsufficiency generally has an underappreciated role in neoplasia. This is no less true in myeloid cells, which are normally regulated by a delicately balanced and interconnected transcriptional network. Detailed understanding of TF dose in this circuitry sheds light on the leukemic transcriptome. In this review, we discuss the emerging features of haploinsufficient transcription factors (HITFs). We posit that: (a) monoallelic and biallelic losses can have distinct cellular outcomes; (b) the activity of aTFexists in a greater range than the traditional Mendelian genetic doses; and (c) how a TF is deleted or mutated impacts the cellular phenotype. The net effect of a HITF is a myeloid differentiation block and increased intercellular heterogeneity in the course of myeloid neoplasia.
引用
收藏
页码:571 / 598
页数:28
相关论文
共 50 条
[21]   Extracellular Vesicles in Myeloid Neoplasms [J].
Karantanou, Christina ;
Minciacchi, Valentina Rene ;
Karantanos, Theodoros .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
[22]   Myeloid Neoplasms with Germline Predisposition [J].
Geyer, Julia T. .
PATHOBIOLOGY, 2019, 86 (01) :53-61
[23]   Transcription factors and translocations in lymphoid and myeloid leukemia [J].
HN Crans ;
KM Sakamoto .
Leukemia, 2001, 15 :313-331
[24]   Transcription factors and translocations in lymphoid and myeloid leukemia [J].
Crans, HN ;
Sakamoto, KM .
LEUKEMIA, 2001, 15 (03) :313-331
[25]   Myeloid Neoplasms [J].
Subtil, Antonio .
CLINICS IN LABORATORY MEDICINE, 2017, 37 (03) :575-+
[26]   PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword [J].
Csizmar, Clifford M. ;
Saliba, Antoine N. ;
Swisher, Elizabeth M. ;
Kaufmann, Scott H. .
CANCERS, 2021, 13 (24)
[27]   Therapy-related myeloid neoplasms following treatment with radioiodine [J].
Schroeder, Thomas ;
Kuendgen, Andrea ;
Kayser, Sabine ;
Kroeger, Nicolaus ;
Braulke, Friederike ;
Platzbecker, Uwe ;
Klaerner, Viola ;
Zohren, Fabian ;
Haase, Detlef ;
Stadler, Michael ;
Schlenk, Richard ;
Czibere, Akos G. ;
Bruns, Ingmar ;
Fenk, Roland ;
Gattermann, Norbert ;
Haas, Rainer ;
Kobbe, Guido ;
Germing, Ulrich .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02) :206-212
[28]   Landscape of biallelic DNMT3A mutant myeloid neoplasms [J].
Kawashima, Naomi ;
Kubota, Yasuo ;
Bravo-Perez, Carlos ;
Guarnera, Luca ;
Williams, Nakisha D. ;
Durmaz, Arda ;
Witt, Michaela ;
Ahmed, Arooj ;
Gurnari, Carmelo ;
Maciejewski, Jaroslaw P. ;
Visconte, Valeria .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
[29]   Current Understanding of DDX41 Mutations in Myeloid Neoplasms [J].
Kim, Kunhwa ;
Ong, Faustine ;
Sasaki, Koji .
CANCERS, 2023, 15 (02)
[30]   Updates in molecular genetics of therapy-related myeloid neoplasms [J].
Cantu, Miguel Dario .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (03) :182-186